| | | | | The EU executive said on Friday that it had asked Czech authorities to clarify a decision to ask states to test exports to the country for African swine fever. | | |
| | | A federal judge on Thursday dismissed a pair of patent infringement lawsuits by Teva Pharmaceutical Industries Ltd that sought to block Eli Lilly and Co from bringing its migraine drug Emgality to market in the United States. | | |
| | | Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches. | | |
| | | Britain's biotechnology industry has raised a bumper 1.56 billion pounds ($2.05 billion) in the first eight months of this year, surpassing the 1.2 billion reached in the whole of 2017, despite anxiety in the sector about the fallout from Brexit. | | |
| | | Pfizer Inc said on Thursday that its once-daily oral drug to treat a rare form of lung cancer received approval from the U.S. Food and Drug Administration. | | |
| | | (Reuters Health) - Older adults with bigger social networks of family members and close friends may be better at staying on top of recommended preventive health screenings and checkups than their more isolated peers, a UK study suggests. | | |
| | | (Reuters Health) - Schools that install a lot of indoor cameras may not be improving security while in fact making children feel less safe, a U.S. study suggests. | | |
| | | (Reuters Health) - Three in five patients hospitalized for heart attacks or other serious cardiovascular problems have at least a moderate risk of falling after they go home, and this risk is tied to higher odds of premature death, a U.S. study suggests. | | |
| | | (Reuters Health) - Adults who have a regular bedtime are likely to weigh less than those who don't, to have lower blood sugar and to face a lower risk of heart disease and diabetes, according to a U.S. study. | | |
| | | Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country. | | |
| | | Alnylam Pharmaceuticals Inc said on Thursday it might have to hold off on plans to seek an accelerated approval for its gene-silencing drug, which showed effectiveness in a late-stage trial based on early data. | | |
|
| |
